The earliest reference to antibodies came from Emil von Behring and Shibasabura Kitasato in 18901. In a landmark publication they showed that the transfer of therapeutic serum from animals immunized against diphtheria to animals suffering from it could cure the infected animals1,2. The potential for treatment in humans was immediately apparent and Behring was later awarded the Nobel Prize for this work in 19013.
In 1900 Paul Ehrlich, proposed the side-chain theory, where he hypothesized that side chain receptors on cells bind to a given pathogen. He was the first to propose a model for an antibody molecule in which the antibody was branched and consisted of multiple sites for binding to foreign material, known as antigen, and for the activation of the complement pathway. This model agreed with the ‘lock and key’ hypothesis for enzymes proposed by Emil Fischer4,5.
Astrid Fagraeus in 1948 described that plasma B cells are specifically involved in antibody generation and by 1957 Frank Burnet and David Talmage had developed the clonal selection theory6. This stated that a lymphocyte makes a single specific antibody molecule that is determined before it encounters an antigen, which was in contrast to the instructive theory developed by Linus Pauling in 1940 where the antigen acted as a template for the antibody7.
By 1959 Gerald Edelman and Rodney Porter independently published the molecular structure of antibodies8,9, for which they were later jointly awarded the Nobel Prize in 197210. The first atomic resolution structure of an antibody fragment was published in 197311 and this was quickly followed by the invention of monoclonal antibodies12 in 1975 by Georges Köhler and César Milstein signaling the start of the modern era of antibody research and discovery.
Figure 1: Antibody research has come a long way from its earliest reference by Emil Von Behring in 1890.
GenScript’s Antibody Engineering group can build antibody library with up to 1010 individual clones, to speed up your antibody discovery efforts.
GenScript’s advanced Antibody Sequencing technology offers fast and professional sequencing services for your monoclonal antibodies.
GenScript has developed several cell-based ADCC/CDC functional assays to profile the efficacy and potency of your therapeutic antibodies using proprietary recombinant effector cells.
GenScript scientists’ extensive experience in antibody engineering can provide superior services such as antibody humanization, affinity maturation and more.
With solid expertise in recombinant antibody (rAb) production techniques, GenScript provides a comprehensive rAb service portfolio that deliver microgram to gram quantities of pure rAb for each stage of your Ab drug discovery program.
GenScript offers over 120 tumor and inflammation models for evaluation of in vivo efficacy, PK/PD, biomarker and bioanalysis studies. GenScript Anti-idiotype Antibody services are also a powerful tool for antibody drug PK/PD and immunogenicity studies.
You can also view our Recombinant Antibody Service Selection Guide to identify services that are the best match for your application.
Our customer service repsentatives are available 24 hours a day, Monday through Friday, to assist you.